Discontinuation Order of Vasopressors in Septic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the incidence of hypotension based on the discontinuation order of norepinephrine and vasopressin in patients receiving concomitant norepinephrine and vasopressin infusions for the treatment of septic shock.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypotension in the Weaning From Vasopressor Drugs

NCT05506319

Septic Shock

COMPLETED PHASE4

Systematic Adjunction of Vasopressine in Septic Shock

NCT07052084

Septic Shock

NOT_YET_RECRUITING PHASE3

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063

Septic Shock

COMPLETED

Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock

NCT06471231

Septic Shock Renal Function Replacement

RECRUITING PHASE4

Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock

NCT06125184

Kidney Injury, Acute Cardiac Function Failed

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are little data regarding the discontinuation of vasopressors in patients with septic shock. Therefore, the investigators intend to evaluate the incidence of hypotension based on the discontinuation order of norepinephrine and vasopressin in patients receiving concomitant norepinephrine and vasopressin infusions for the treatment of septic shock.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vasopressin

Vasopressin will be reduced first (0.01 U/hour)

Group Type ACTIVE_COMPARATOR

Vasopressin

Intervention Type DRUG

Vasopressin will be reduced first (0.01 U/hour)

Norepinephrine

Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)

Group Type ACTIVE_COMPARATOR

Norepinephrine

Intervention Type DRUG

Norepinephrine will be reduced first (0.1 microgram/kg/hour)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vasopressin

Vasopressin will be reduced first (0.01 U/hour)

Intervention Type DRUG

Norepinephrine

Norepinephrine will be reduced first (0.1 microgram/kg/hour)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients 20 years of age or older
* patients of receiving concomitant therapy with norepinephrine and vasopressin for teh management of septic shock
* patients began to reduce the vasopressor

Exclusion Criteria

* patients who expired or had care withdrawn while receiving norepinephrine and vasopressin
* patients being transferred into the ICU from an outside facility or the operating room
* patients who are suspected to have vasopressin deficiency (eg. HPA axis dysfunction, empty sella)
* acute myocardial infarction or Congestive heart failure (NYHA functional classification III or IV)
* acute mesenteric ischemia
* patients who were received other vasopressor except for norepinephrine or vasopressin

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No